NNOX stock forecast, quote, news & analysis
Nano X Imaging Ltd is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform... Show more
Nano-X Imaging (NNOX) Stock Analysis: Navigating Q3 Miss and Bold 2026 Guidance
Key Takeaways
- Nano-X Imaging reported Q3 2025 revenue and earnings below expectations, yet shares rose on optimistic 2026 revenue guidance of $35 million.
- Recent analyst coverage remains limited, with mixed price targets reflecting ongoing commercialization challenges.
- Stock has shown volatility tied to operational updates and imaging technology milestones.
- Strong balance sheet supports expansion of Nanox.ARC systems amid global healthcare demand.
- Key 2026 focus: Revenue ramp-up, regulatory approvals, and partnerships in medical imaging.
Current Market Snapshot
In recent weeks, Nano-X Imaging (NNOX) stock has exhibited heightened volatility, reflecting investor reactions to quarterly results and forward guidance. The shares experienced an initial dip following the Q3 earnings miss but rebounded sharply on bullish 2026 projections. Trading patterns highlight sensitivity to company-specific news, with broader market rotations in healthcare and tech sectors adding pressure. Technical indicators suggest consolidation around key support levels, as sentiment balances execution risks against long-term disruption potential in digital X-ray imaging. Volume spikes accompany updates on product deployments and regulatory progress.
Recent Developments Driving NNOX Price Action
Nano-X Imaging Ltd. (NNOX), a developer of innovative digital X-ray imaging systems, has been in the spotlight due to key financial and operational updates over the past 30 days. The company's Q3 2025 earnings, released in late November 2025, marked a pivotal moment. Revenue fell short of analyst expectations, as did earnings per share, underscoring persistent challenges in scaling commercialization of the Nanox.ARC platform. Despite the miss, the stock surged in pre-market trading and held gains through subsequent sessions. This resilience stemmed directly from management's issuance of aggressive 2026 revenue guidance targeting $35 million—a figure that implies significant acceleration from prior quarters and signals confidence in system installations and service contracts.
Operational progress bolstered the positive sentiment. Nano-X highlighted advancements in Nanox.ARC deployments, including live demonstrations and initial sales traction in select markets. The company also referenced ongoing regulatory clearances, building on prior FDA approvals for components of its imaging ecosystem. These updates addressed investor concerns over execution timelines, a recurring theme since the firm's public debut.
Analyst reactions were measured but supportive. Sources like TipRanks noted two analysts maintaining coverage with 12-month price targets, reflecting a cautious "hold" consensus amid the transition from R&D to revenue generation. No major downgrades emerged post-earnings, unlike some peers in medtech. Broader industry tailwinds, such as rising demand for cost-effective imaging solutions in emerging markets, indirectly supported NNOX. Macro factors, including interest rate expectations and healthcare spending trends, played a muted role, with stock moves primarily event-driven.
Price action mirrored this narrative: a post-earnings pullback gave way to a multi-day rally, peaking on guidance reiterations before settling into a tighter range. Trading volume elevated during the earnings window, indicating strong institutional interest. Social media buzz on platforms like X amplified retail focus on the 2026 outlook, contributing to short-term momentum. Overall, these developments shifted sentiment from skepticism over near-term hurdles to optimism about scalable growth, driving net positive price performance despite the fundamentals shortfall.
2026 Outlook and Key Factors to Monitor
As Nano-X Imaging enters 2026, investors should track execution against the $35 million revenue target, which hinges on Nanox.ARC installations and recurring service revenue. Progress in international partnerships and regulatory approvals in key regions like Europe and Asia will be critical for global expansion. The company's digital tomosynthesis technology positions it well amid industry shifts toward affordable, high-resolution imaging, but competition from established players like GE Healthcare and Siemens Healthineers looms large.
Balance sheet strength, with ample cash reserves, supports R&D and marketing investments, yet margin improvement remains a watchpoint as production scales. Macroeconomic factors, including healthcare budgets and supply chain stability, could influence deployment timelines. Analyst updates and quarterly progress on system sales will shape consensus views. Long-term, Nano-X's mission to democratize medical imaging offers upside if commercialization milestones are met, balanced against execution risks in a capital-intensive sector.
Momentum Indicator for NNOX turns negative, indicating new downward trend
NNOX saw its Momentum Indicator move below the 0 level on June 08, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In of the 96 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for NNOX turned negative on June 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
NNOX moved below its 50-day moving average on June 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NNOX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NNOX advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .
NNOX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 118 cases where NNOX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.832) is normal, around the industry mean (10.931). P/E Ratio (0.000) is within average values for comparable stocks, (63.298). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.716). NNOX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (8.313) is also within normal values, averaging (22.338).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NNOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development of medical imaging systems
Industry MedicalNursingServices